We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Global Blood Glucose Monitoring Devices Market to Reach USD 13 Billion by 2023

By LabMedica International staff writers
Posted on 16 Mar 2020
The global blood glucose monitoring devices (BGMDs) market was valued at nearly USD 8 billion in 2018 and is projected to grow at a fast-paced CAGR of approximately 11% to reach USD 13 billion by 2023, driven by the phenomenal sales growth of new revolutionary continuous glucose monitoring systems (CGMs). More...
However, the growth of CGMs will be offset by a steady decline in the blood glucose meters (BGMs) segment due to continued extreme price competition/downward pricing pressure, lowered test-strip reimbursement, and market saturation of lower-cost meters, among other factors.

These are the latest findings of Research and Markets (Dublin, Ireland), a leading market research store.

The overall BGMDs market is being driven by several positive factors, including a strong demand for discreet, accurate CGM devices that provide convenient blood glucose monitoring 24/7 and eliminate frequent/cumbersome and painful fingersticks; steadily increasing awareness and adoption of new, next-generation CGMs on the back of strong sales/marketing/advertising and physician referrals; solid clinical outcomes due to the ability to improve the accuracy of insulin delivery and improve glycemic control or time-in-range (TIR) via continuous (24/7) glucose monitoring; the ability to integrate lucrative CGM sensors into fast-growing next-generation hybrid closed-loop insulin pump systems, better patient awareness and physician understanding of glucose trends and impact of diet/medication/exercise/lifestyle factors due to the use of smartphone-driven digital health coaching apps, resulting in improved diabetes management; ability to lower overall healthcare costs; solid reimbursement; low CGM market penetration (due to newness of technology), leaving much room for market growth in a large and expanding diabetes population; and sales of lucrative recurring CGM disposables (sensors) and accessories.

Related Links:
Research and Markets


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Portable Electronic Pipette
Mini 96
New
Gel Cards
DG Gel Cards
New
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Colorectal cancer under the microscope (Photo courtesy of Adobe Stock)

Unique Microbial Fingerprint to Improve Diagnosis of Colorectal Cancer

Colorectal cancer is the fourth most common cancer in the UK and the second deadliest. New research has revealed that it carries a unique microbial fingerprint, which could help doctors better understand... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.